• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

ATL’s Fill joins pharmaceutical start-up

Article

After brokering the sale of ATL Ultrasound to Royal Philips Electronics of the Netherlands (SCAN 8/5/98), chairman and CEO Dennis Fill has moved on to a new venture. Fill last month was named president and CEO of Cytran, a new

After brokering the sale of ATL Ultrasound to Royal Philips Electronics of the Netherlands (SCAN 8/5/98), chairman and CEO Dennis Fill has moved on to a new venture. Fill last month was named president and CEO of Cytran, a new pharmaceutical company based in Kirkland, WA. Effective March 1, he replaced Cytran’s former CEO, Philip Syrdal. Fill served as CEO of Bothell, WA-based ATL from 1987 through December 1998. Cytran was founded in 1991 and develops peptide compounds for the treatment of cancer and modulation of the immune system.

Related Videos
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Related Content
© 2024 MJH Life Sciences

All rights reserved.